CN106659779B - 双特异性四价抗体及其制造和使用方法 - Google Patents

双特异性四价抗体及其制造和使用方法 Download PDF

Info

Publication number
CN106659779B
CN106659779B CN201580036408.7A CN201580036408A CN106659779B CN 106659779 B CN106659779 B CN 106659779B CN 201580036408 A CN201580036408 A CN 201580036408A CN 106659779 B CN106659779 B CN 106659779B
Authority
CN
China
Prior art keywords
cancer
antibody
egfr
gly
bispecific tetravalent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580036408.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106659779A (zh
Inventor
高泽人
菲尔·谭
布莱恩·科瓦切维奇
布莱尔·伦肖
杰弗里·阿达莫
麦雅丝
卓识
陈澜
朱义
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Bailidote Biological Pharmaceutical Co ltd
Original Assignee
Sichuan Baili Pharmaceutical Co Ltd
Seattle Immunization Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202110471052.7A priority Critical patent/CN113512121B/zh
Priority to CN202110470818.XA priority patent/CN113512120B/zh
Priority to CN202110470743.5A priority patent/CN113105551B/zh
Priority to CN202110470781.0A priority patent/CN113105552B/zh
Priority to CN202110471082.8A priority patent/CN113512122B/zh
Priority to CN202110471245.2A priority patent/CN113512123B/zh
Priority to CN202110471476.3A priority patent/CN113150165B/zh
Priority to CN202110471392.XA priority patent/CN113105553B/zh
Application filed by Sichuan Baili Pharmaceutical Co Ltd, Seattle Immunization Co filed Critical Sichuan Baili Pharmaceutical Co Ltd
Publication of CN106659779A publication Critical patent/CN106659779A/zh
Application granted granted Critical
Publication of CN106659779B publication Critical patent/CN106659779B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580036408.7A 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法 Active CN106659779B (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN202110470743.5A CN113105551B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110470781.0A CN113105552B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110471082.8A CN113512122B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110471245.2A CN113512123B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110471052.7A CN113512121B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110471392.XA CN113105553B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110471476.3A CN113150165B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110470818.XA CN113512120B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462095348P 2014-12-22 2014-12-22
US62/095,348 2014-12-22
PCT/US2015/066951 WO2016106157A1 (en) 2014-12-22 2015-12-19 Bispecific tetravalent antibodies and methods of makiing and using thereof

Related Child Applications (8)

Application Number Title Priority Date Filing Date
CN202110471245.2A Division CN113512123B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110471392.XA Division CN113105553B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110470781.0A Division CN113105552B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110471082.8A Division CN113512122B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110471476.3A Division CN113150165B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110470818.XA Division CN113512120B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110470743.5A Division CN113105551B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110471052.7A Division CN113512121B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法

Publications (2)

Publication Number Publication Date
CN106659779A CN106659779A (zh) 2017-05-10
CN106659779B true CN106659779B (zh) 2021-05-18

Family

ID=56151464

Family Applications (11)

Application Number Title Priority Date Filing Date
CN201580036408.7A Active CN106659779B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN201580073430.9A Active CN107206074B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制备和使用方法
CN202110471245.2A Active CN113512123B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110471052.7A Active CN113512121B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110470818.XA Active CN113512120B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110471476.3A Active CN113150165B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110471082.8A Active CN113512122B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110471392.XA Active CN113105553B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202311507433.1A Pending CN117467017A (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制备和使用方法
CN202110470743.5A Active CN113105551B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110470781.0A Active CN113105552B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法

Family Applications After (10)

Application Number Title Priority Date Filing Date
CN201580073430.9A Active CN107206074B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制备和使用方法
CN202110471245.2A Active CN113512123B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110471052.7A Active CN113512121B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110470818.XA Active CN113512120B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110471476.3A Active CN113150165B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110471082.8A Active CN113512122B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110471392.XA Active CN113105553B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202311507433.1A Pending CN117467017A (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制备和使用方法
CN202110470743.5A Active CN113105551B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法
CN202110470781.0A Active CN113105552B (zh) 2014-12-22 2015-12-19 双特异性四价抗体及其制造和使用方法

Country Status (22)

Country Link
US (2) US10919977B2 (https=)
EP (3) EP3237005B1 (https=)
JP (2) JP6947639B2 (https=)
KR (4) KR102548827B1 (https=)
CN (11) CN106659779B (https=)
AU (1) AU2015369831B2 (https=)
CA (2) CA3138083A1 (https=)
DK (1) DK3237005T3 (https=)
ES (2) ES2962675T3 (https=)
FI (1) FI3237005T3 (https=)
HR (1) HRP20241502T1 (https=)
HU (1) HUE069256T2 (https=)
IL (3) IL286835B2 (https=)
LT (1) LT3237005T (https=)
NZ (1) NZ732628A (https=)
PL (1) PL3237005T3 (https=)
PT (1) PT3237005T (https=)
RS (1) RS66070B1 (https=)
SG (1) SG11201704741PA (https=)
SI (1) SI3237005T1 (https=)
SM (1) SMT202400477T1 (https=)
WO (2) WO2016106157A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3138083A1 (en) * 2014-12-22 2016-06-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
US12428483B2 (en) 2014-12-22 2025-09-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
CA2973720A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
CN106632681B (zh) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
CN108948195B (zh) * 2017-05-23 2022-05-31 胡毅 一种抗egfr/pd-l1双靶向抗体、其制备方法及用途
US11987635B2 (en) * 2017-06-25 2024-05-21 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Anti-4-1BB antibodies and methods of making and using thereof
SG11202003237QA (en) * 2017-11-02 2020-05-28 Systimmune Inc Bispecific antibodies and methods of making and using thereof
AU2019207296A1 (en) * 2018-01-15 2020-07-16 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against TIGIT
CN107974461A (zh) * 2018-01-18 2018-05-01 东北农业大学 一种高效表达anti-hEGFR基因的真核表达载体构建方法
CN108220244A (zh) * 2018-01-18 2018-06-29 东北农业大学 一种含重组人表皮生长因子受体抗体基因的cho细胞株、筛选方法及其生产工艺
CA3095373A1 (en) * 2018-04-13 2019-10-17 Affimed Gmbh Nk cell engaging antibody fusion constructs
US20210115152A1 (en) * 2018-05-16 2021-04-22 Arbele Limited Composition of bispecific antibodies and method of use thereof
JP7193058B2 (ja) * 2018-08-08 2022-12-20 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） インコーポレイテッド Ｃｄ４７およびｈｅｒ２を標的とする組換え二機能性タンパク質
CN110850068B (zh) * 2018-08-21 2023-08-15 上海恒润达生生物科技股份有限公司 一种嵌合抗原受体亲和力检测方法
EP3853247A2 (en) * 2018-09-19 2021-07-28 Alpine Immune Sciences, Inc. Methods and uses of variant cd80 fusion proteins and related constructs
JP7575100B2 (ja) * 2018-11-13 2024-10-29 ジェイエヌ バイオサイエンシーズ エルエルシー 免疫細胞活性化のための二重特異性抗体
JP7680358B2 (ja) * 2019-01-30 2025-05-20 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー 癌抗原を標的とするｄｎａコード化二重特異性ｔ細胞エンゲージャーおよび癌治療薬における使用方法
CN114450306B (zh) * 2019-07-26 2024-04-05 Abl生物公司 抗egfr/抗4-1bb双特异性抗体及其用途
BR112022002067A2 (pt) * 2019-08-08 2022-06-14 Regeneron Pharma Formatos de molécula de ligação ao antígeno
JP7592712B2 (ja) * 2019-11-06 2024-12-02 システィミューン， インク． ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法
AU2021224200A1 (en) * 2020-02-19 2022-09-08 Denali Therapeutics Inc. Engineered anti-HER2 bispecific proteins
TWI908779B (zh) * 2020-03-17 2025-12-21 美商西雅圖免疫公司 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
CN111548424A (zh) * 2020-06-05 2020-08-18 上海科弈药业科技有限公司 一种靶向egfr与cd47的多功能融合蛋白及其应用
MX2023003304A (es) * 2020-09-21 2023-05-09 Systimmune Inc Complejo de union de egfr y metodo de fabricacion y uso del mismo.
AU2022333089A1 (en) * 2021-08-25 2024-02-29 Systimmune, Inc. Bispecific tetravalent antibody targeting egfr and her3
WO2023044483A2 (en) * 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
JP2024536275A (ja) * 2021-10-03 2024-10-04 システィミューン， インク． がんを治療する方法及びその医薬組成物
WO2023083381A1 (zh) * 2021-11-15 2023-05-19 成都百利多特生物药业有限责任公司 双特异性抗体-喜树碱类药物偶联物及其医药用途
WO2023241480A1 (zh) * 2022-06-13 2023-12-21 三优生物医药(上海)有限公司 抗pd-l1、vegf和egfr三特异性抗体及其应用
EP4580673A2 (en) * 2022-08-31 2025-07-09 SystImmune, Inc. Biepitopic tetravalent antibody targeting egfr
CN116063564A (zh) * 2022-10-08 2023-05-05 盛禾(中国)生物制药有限公司 一种纯化融合蛋白的方法
CN118829655A (zh) * 2023-02-15 2024-10-22 浙江时迈药业有限公司 Egfr和lag3双靶向的双特异性抗体及其用途
CN121443647A (zh) * 2023-07-07 2026-01-30 四川科伦博泰生物医药股份有限公司 EGFR/c-MET双特异性结合蛋白及其用途
AU2024317606A1 (en) * 2023-07-29 2026-02-26 Chimagen Biosciences, Ltd Modified type e multi-specific antibodies
WO2025117871A1 (en) * 2023-11-29 2025-06-05 Systimmune, Inc. Bispecific tetravalent antibody targeting her2 and her3
WO2025140662A1 (en) * 2023-12-29 2025-07-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-egfr/her3 antibodies and uses thereof
TW202540193A (zh) * 2024-03-14 2025-10-16 大陸商珠海普米斯生物科技有限公司 雙特異性抗體、抗體藥物偶聯物及其應用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102369215A (zh) * 2009-04-02 2012-03-07 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
CN104203981A (zh) * 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
CN104211814A (zh) * 2013-05-29 2014-12-17 三星电子株式会社 用于消耗靶膜蛋白的组合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2200753B (en) 1986-12-23 1991-01-23 Brookes & Gatehouse Speed measurement device
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2473144C (en) * 2002-02-05 2013-05-28 Genentech, Inc. Protein purification
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
CN101061140B (zh) * 2004-09-17 2015-07-01 多曼蒂斯有限公司 单价结合cd40l的组合物和应用方法
CA2654794A1 (en) * 2006-06-14 2007-12-21 Imclone Systems Incorporated Lyophilized formulations of anti-egfr antibodies
WO2008140493A2 (en) * 2006-11-21 2008-11-20 The Regents Of The University Of Californina Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
MY152068A (en) * 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
WO2010111625A1 (en) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
MX2011010166A (es) 2009-04-07 2011-10-11 Roche Glycart Ag Anticuerpos biespecificos anti-erbb-3/anti-c-met.
WO2011028811A2 (en) * 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
EP2496598B1 (en) * 2009-11-04 2017-08-02 Affibody AB Her3 binding polypeptides
JP2014504850A (ja) * 2010-09-30 2014-02-27 メルク・シャープ・エンド・ドーム・コーポレイション 抗ｈｅｒ３抗体の製造、特徴づけ及びその用途
EP2655414B1 (en) * 2010-12-23 2018-08-29 Roche Diagniostics GmbH Bispecific binding agent
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US20140170148A1 (en) * 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
CN103796678B (zh) * 2011-04-20 2018-02-27 健玛保 针对her2的双特异性抗体
WO2012147713A1 (ja) * 2011-04-25 2012-11-01 第一三共株式会社 抗ｂ７－ｈ３抗体
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
CN102250247B (zh) 2011-06-15 2013-06-19 常州亚当生物技术有限公司 一种抗vegf/ang2双特异性抗体及其应用
WO2013096346A1 (en) * 2011-12-22 2013-06-27 Development Center For Biotechnology Bispecific t-cell activator antibody
US20130259867A1 (en) * 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
WO2014012082A2 (en) * 2012-07-13 2014-01-16 Zymeworks Inc. Multivalent heteromultimer scaffold design an constructs
MX361088B (es) * 2012-11-21 2018-11-26 Janssen Biotech Inc Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
CN104688740A (zh) * 2012-12-21 2015-06-10 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
JP2016514676A (ja) * 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体
CA3138083A1 (en) * 2014-12-22 2016-06-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102369215A (zh) * 2009-04-02 2012-03-07 罗切格利卡特公司 包含全长抗体和单链Fab片段的多特异性抗体
CN104203981A (zh) * 2011-12-19 2014-12-10 合成免疫股份有限公司 双特异性抗体分子
CN104211814A (zh) * 2013-05-29 2014-12-17 三星电子株式会社 用于消耗靶膜蛋白的组合物

Also Published As

Publication number Publication date
WO2016106157A1 (en) 2016-06-30
CN113105551B (zh) 2024-10-25
CN113105553B (zh) 2024-09-10
EP3237005B1 (en) 2024-09-18
KR20230149328A (ko) 2023-10-26
US10919977B2 (en) 2021-02-16
AU2015369831A1 (en) 2017-06-29
CN113512123B (zh) 2024-10-25
CN113512123A (zh) 2021-10-19
LT3237005T (lt) 2024-11-11
KR20250094744A (ko) 2025-06-25
NZ732628A (en) 2019-01-25
CN107206074B (zh) 2023-12-01
JP2018509175A (ja) 2018-04-05
IL305193A (en) 2023-10-01
HUE069256T2 (hu) 2025-02-28
IL252811B (en) 2021-10-31
KR20230104988A (ko) 2023-07-11
CN113105553A (zh) 2021-07-13
RS66070B1 (sr) 2024-11-29
CN106659779A (zh) 2017-05-10
DK3237005T3 (en) 2024-11-18
HRP20241502T1 (hr) 2025-01-03
FI3237005T3 (fi) 2024-12-02
EP3237005A4 (en) 2018-05-23
JP6947639B2 (ja) 2021-10-13
CN113512120B (zh) 2024-08-02
EP4491195A2 (en) 2025-01-15
CN117467017A (zh) 2024-01-30
CN113512122A (zh) 2021-10-19
CN113512121A (zh) 2021-10-19
CN113150165B (zh) 2024-09-03
IL286835B2 (en) 2024-03-01
US20170369587A1 (en) 2017-12-28
CN113512122B (zh) 2024-09-10
PL3237005T3 (pl) 2025-01-27
AU2015369831B2 (en) 2019-07-11
US10717783B2 (en) 2020-07-21
SMT202400477T1 (it) 2025-01-14
CN113105551A (zh) 2021-07-13
ES2962675T3 (es) 2024-03-20
CA2969867A1 (en) 2016-06-30
CN113512121B (zh) 2024-10-25
EP3237006A1 (en) 2017-11-01
EP3237006A4 (en) 2018-05-30
KR102823201B1 (ko) 2025-06-23
JP7335290B2 (ja) 2023-08-29
CN113150165A (zh) 2021-07-23
IL286835B1 (en) 2023-11-01
IL252811A0 (en) 2017-08-31
EP4491195A3 (en) 2025-04-02
KR102548827B1 (ko) 2023-06-30
EP3237005A1 (en) 2017-11-01
CN107206074A (zh) 2017-09-26
CA3138083A1 (en) 2016-06-30
CN113105552B (zh) 2024-09-20
KR102590385B1 (ko) 2023-10-18
WO2016106158A1 (en) 2016-06-30
KR20170091162A (ko) 2017-08-08
CA2969867C (en) 2022-01-25
CN113512120A (zh) 2021-10-19
US20170073418A1 (en) 2017-03-16
ES2995733T3 (en) 2025-02-11
SG11201704741PA (en) 2017-07-28
IL286835A (en) 2021-10-31
SI3237005T1 (sl) 2025-02-28
EP3237006B1 (en) 2023-08-16
CN113105552A (zh) 2021-07-13
JP2021119149A (ja) 2021-08-12
PT3237005T (pt) 2024-11-18

Similar Documents

Publication Publication Date Title
CN106659779B (zh) 双特异性四价抗体及其制造和使用方法
TWI899079B (zh) 抗ror1/抗cd3雙特異性結合分子
CN108368170B (zh) 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
CN114650844A (zh) 抗cd47抗体、可活化抗cd47抗体及其使用方法
CN114702586A (zh) 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
CN116199785A (zh) 多特异性抗体及其制备和使用方法
US12428483B2 (en) Bispecific tetravalent antibodies and methods of making and using thereof
KR20250075712A (ko) B7h3/pdl1 이중특이성 항체 및 이의 약학 조성물과 응용
HK1233941A1 (en) Bispecific tetravalent antibodies and methods of making and using thereof
HK40120554A (en) Bispecific tetravalent antibodies and methods of makiing and using thereof
HK1233941B (zh) 双特异性四价抗体及其制造和使用方法
WO2025117871A1 (en) Bispecific tetravalent antibody targeting her2 and her3

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1233941

Country of ref document: HK

CB02 Change of applicant information

Address after: No. 15318, 95 Street northeast, Redmond, Washington, U. S.

Applicant after: Seattle Immunization Co.

Address before: No. 2023, 120th Avenue, northeast of Baer, Washington, D.C.

Applicant before: Seattle Immunization Co.

CB02 Change of applicant information
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Gao Zeren

Inventor after: Phil Tan

Inventor after: Brian Kovacevic

Inventor after: Blair Renshaw

Inventor after: Jeffrey Adamo

Inventor after: Ma Ya Si

Inventor after: Zhuo Shi

Inventor after: Chen Lan

Inventor after: Zhu Yi

Inventor before: Gao Zeren

Inventor before: Phil Tan

Inventor before: Brian Kovacevic

Inventor before: Blair Renshaw

Inventor before: Jeffrey Adamo

Inventor before: Ma Ya Si

Inventor before: Zhuo Shi

Inventor before: Chen Lan

TA01 Transfer of patent application right

Effective date of registration: 20180907

Address after: 15318 street, 95 northeast street, Redmond, Washington, USA

Applicant after: Seattle Immunization Co.

Applicant after: SICHUAN BAILI PHARM Co.,Ltd.

Address before: 15318 street, 95 northeast street, Redmond, Washington, USA

Applicant before: Seattle Immunization Co.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220606

Address after: No. 15318, 95 Street northeast, Redmond, Washington, U. S.

Patentee after: Seattle Immunization Co.

Patentee after: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Address before: No. 15318, 95 Street northeast, Redmond, Washington, U. S.

Patentee before: Seattle Immunization Co.

Patentee before: SICHUAN BAILI PHARM Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240621

Address after: No. 139 Baili Road, Chengdu Cross Strait Science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province, 611130

Patentee after: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Country or region after: China

Address before: 15318 Northeast 95th Street, Redmond, Washington, USA

Patentee before: Seattle Immunization Co.

Country or region before: U.S.A.

Patentee before: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Country or region before: China